Search - tctmd.com

Displaying 1 - 20 of 55

Sort: Relevancy | Date

Presentation TCT 2025

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

Presenter: Yousif Ahmad

October 28, 2025

Presentation TCT 2025

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2025

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

Presenter: Amitoj Singh

October 27, 2025

Presentation TCT 2025

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

Presenter: Asna Aafreen

October 26, 2025

Presentation TCT 2025

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Presenter: Seung Hun Lee

October 26, 2025

Presentation TCT 2024

Debate Pro: Always

Presenter: Marco Valgimigli

October 30, 2024

Presentation TCT 2024

Debate Con: Never

Presenter: Dominick Angiolillo

October 30, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

Presenter: Wadie David

October 24, 2023

Presentation TCT 2023

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Presenter: Seung-Yul Lee

October 24, 2023

Presentation TCT 2022

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

Presenter: Rayan Jo Rachwan

September 18, 2022

Presentation TCT 2022

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Presenter: Davide Capodanno

September 18, 2022

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2020

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

Presenter: Mohammad Saud Khan

October 14, 2020

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

Case Resolution: How Did I Treat and What Happened?

Presenter: Amit Vora

September 26, 2019

Advertisement

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Debate Pro: Always

Debate Con: Never

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Case Resolution: How Did I Treat and What Happened?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content